Our main objective in this study was to evaluate the efficacy of PRMT5 inhibition in combination with Gem-based chemotherapy using clinically relevant orthotopic and metastatic PDX mouse models of pancreatic cancer. This evidence concerns the gene PRMT5 and familial pancreatic carcinoma.